Raymond James Financial
DSGN icon

Raymond James Financial’s Design Therapeutics DSGN Stock Holding History

Raymond James Financial’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Buy
138,521
+30,072
+28% +$375K ﹤0.01% 3481
2026
Q1 		$1.15M Sell
108,449
-1,314
-1% -$13.3K ﹤0.01% 3753
2025
Q4 		$1.03M Buy
+109,763
New +$859K ﹤0.01% 3753

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Raymond James Financial's DSGN Position: Q2 2026 in Review

Raymond James Financial increased its Design Therapeutics (DSGN) stake by 28% in Q2 2026, buying an estimated $375K and bringing the position to 138,521 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #3481.

Raymond James Financial first reported a position in DSGN in Q4 2025 and has held it in 3 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Raymond James Financial held 138,521 shares of Design Therapeutics worth $2M as of Q2 2026.
  • Raymond James Financial bought 30,072 Design Therapeutics shares in Q2 2026, an estimated $375K.
  • Design Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3481 holding.
  • Raymond James Financial first reported a position in Design Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.